The goals of the PDT Physics core are to: 1) Provide Laser and other light source support for all projects; 2)Perform high-quality and reliable in vivo light dosimetry for projects (1,3,4 and 5); 3) Provide absolute lightdosimetry standards for all projects; 4) Provide explicit PDT dosimetry for tissue optical properties, drugconcentrations, and tissue oxygenation before, after, and during PDT.The physics core is responsible for calibrating the absolute output power of laser sources, ensuring that theyare traceable to standards maintained by the National Institute of Science and Technology (NIST). The coreperforms in vivo light dosimetry to achieve accurate light fluence measurement in PDT treatments, such asthe Intraperitoneal and Pleural PDT studies. Laser equipment operating at treatment wavelengths (532-730nm) for PDT are maintained, along with light sources covering wavelengths between 400 - 900 nm forabsorption and fluorescence spectroscopy. The physics core translates the spectroscopic techniquesdeveloped in the physics project for in vivo PDT dosimetry into clinical trials. The physics core ensures lasersafety, maintains quality assurance of physics equipment, and works to characterize light fluencedistributions in tissue. It helps to implement useful technologies developed in the physics project (Project 4)to routine clinical applications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA087971-06A1
Application #
7348013
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Project Start
2008-04-08
Project End
2013-01-31
Budget Start
2008-04-08
Budget End
2009-01-31
Support Year
6
Fiscal Year
2008
Total Cost
$194,467
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Davis 4th, Richard W; Snyder, Emma; Miller, Joann et al. (2018) Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy. Photochem Photobiol :
Cramer, Gwendolyn; Simone 2nd, Charles B; Busch, Theresa M et al. (2018) Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma. J Thorac Dis 10:S2565-S2573
Ong, Yi Hong; Padawer-Curry, Jonah; Finlay, Jarod C et al. (2018) Determination of optical properties, drug concentration, and tissue oxygenation in human pleural tissue before and after Photofrin-mediated photodynamic therapy. Proc SPIE Int Soc Opt Eng 10476:
Ong, Yi Hong; Kim, Michele M; Huang, Zheng et al. (2018) Reactive Oxygen Species Explicit Dosimetry (ROSED) of a Type 1 Photosensitizer. Proc SPIE Int Soc Opt Eng 10476:
Zhu, Timothy C; Kim, Michele M; Padawer, Jonah et al. (2018) Light Fluence Dosimetry in Lung-simulating Cavities. Proc SPIE Int Soc Opt Eng 10476:
Chandra, Abhishek; Wang, Luqiang; Young, Tiffany et al. (2018) Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiation-induced osteoporosis. FASEB J 32:52-62
Ong, Yi Hong; Finlay, Jarod C; Zhu, Timothy C (2018) Monte Carlo modelling of fluorescence in semi-infinite turbid media. Proc SPIE Int Soc Opt Eng 10492:
Yan, Lesan; Amirshaghaghi, Ahmad; Huang, Dennis et al. (2018) Protoporphyrin IX (PpIX)-Coated Superparamagnetic Iron Oxide Nanoparticle (SPION) Nanoclusters for Magnetic Resonance Imaging and Photodynamic Therapy. Adv Funct Mater 28:
Dimofte, Andreea; Finlay, Jarod; Ong, Yi Hong et al. (2018) A quality assurance program for clinical PDT. Proc SPIE Int Soc Opt Eng 10476:
Ahn, Peter H; Finlay, Jarod C; Gallagher-Colombo, Shannon M et al. (2018) Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy. Photodiagnosis Photodyn Ther 21:28-35

Showing the most recent 10 out of 127 publications